Therapy Area
Roche wins second FDA label expansion for Alecensa in NSCLC
Roche’s Alecensa is now approved as an adjuvant therapy for patients with ALK-positive non-small cell lung cancer (NSCLC).
Roche’s Alecensa is now approved as an adjuvant therapy for patients with ALK-positive non-small cell lung cancer (NSCLC).